Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
DitchCarbon Score
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hangzhou Tigermed's score of 22 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hangzhou Tigermed's reported carbon emissions
In 2023, Hangzhou Tigermed Consulting Co., Ltd. reported total carbon emissions of approximately 2,136,860 kg CO2e globally, with Scope 1 emissions at about 94,270 kg CO2e and Scope 2 emissions at around 2,042,580 kg CO2e. In China, their emissions were significantly higher, totalling approximately 13,341,350 kg CO2e, with Scope 1 emissions of about 124,060 kg CO2e and Scope 2 emissions of approximately 13,217,290 kg CO2e. Over the years, Tigermed has shown fluctuations in emissions, with a notable increase in total emissions from about 1,438,920 kg CO2e in 2021 to the 2023 figures. The company has committed to near-term reduction targets but has not set a net-zero commitment as of now. Their emissions data reflects a focus on managing Scope 1 and Scope 2 emissions, while Scope 3 emissions were reported at a minimal level of 230 kg CO2e in 2021. Tigermed operates within the pharmaceuticals, biotechnology, and life sciences sector, indicating a growing awareness and responsibility towards climate impact in an industry that is increasingly scrutinised for its environmental footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 63,180 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 1,037,878 | 0,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hangzhou Tigermed is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
